Asset Details
Do you wish to reserve the book?
Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable
Do you wish to request the book?
Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable
2020
Overview
Patients with moderate-to-severe atopic dermatitis may have partial or non-durable responses to subcutaneous dupilumab, the first targeted systemic agent approved for this indication. Subsequent management approaches in such patients include optimising topical therapy, considering alternative diagnoses, adjusting the dosage of dupilumab dosage and/or using dupilumab in combination with traditional systemic immunosuppressive agents.
Publisher
Springer International Publishing,Springer Nature B.V
